<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Benitec Biopharma Ltd Adr — News on 6ix</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr</link>
<description>Latest news and press releases for Benitec Biopharma Ltd Adr on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/benitec-biopharma-ltd-adr" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354ead78dffbe2df0e675a.webp</url>
<title>Benitec Biopharma Ltd Adr</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr</link>
</image>
<item>
<title>Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-oral-presentation-of-interim-phase-1b2a-clinical-study-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting</guid>
<pubDate>Tue, 28 Apr 2026 11:00:00 GMT</pubDate>
<description>- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD HAYWARD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:</description>
</item>
<item>
<title>Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development fo...</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-the-only-clinical-stage-therapeutic-in-development-fo</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-to-host-industry-forum-breakfast-event-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference-on-march-10-2026-highlighting-continued-progress-for-bb-301-the-only-clinical-stage-therapeutic-in-development-fo</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026,</description>
</item>
<item>
<title>Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-positive-interim-phase-1b2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-treatment-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-positive-interim-phase-1b2a-results-for-high-dose-bb-301-and-continued-durable-improvements-for-low-dose-bb-301-treatment-at-the-2026-muscular-dystrophy-association-clinical-and-scientific-conference</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>- Oculopharyngeal Muscular Dystrophy (OPMD) Patients treated with low dose BB-301 and high dose BB-301 experienced significant improvements in throat closure,</description>
</item>
<item>
<title>Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-acceptance-of-late-breaking-abstract-for-the-bb-301-phase-1b2a-clinical-treatment-study-at-the-muscular-dystrophy-association-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-acceptance-of-late-breaking-abstract-for-the-bb-301-phase-1b2a-clinical-treatment-study-at-the-muscular-dystrophy-association-clinical-and-scientific-conference</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers,</description>
</item>
<item>
<title>Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-second-quarter-133000334</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-second-quarter-133000334</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>-The first 4 Patients enrolled into Cohort 1 of the BB-301 Phase 1b/2a treatment study have completed the 12-month statistical follow-up period, and all 4 Completers were formal Responders to BB-301 at the 12-month follow-up timepoint demonstrating durable response to BB-301- -Patient 1 of Cohort 1 completed the 24-month follow-up timepoint, and at the 24-month post-treatment timepoint Patient 1 continued to experience the disease-modifying effects of BB-301, with deepening improvements in post-</description>
</item>
<item>
<title>Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-provides-positive-long-130000900</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-provides-positive-long-130000900</guid>
<pubDate>Sun, 11 Jan 2026 13:00:00 GMT</pubDate>
<description>• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint • The first 4 patients enrolled into Cohort 1 have completed th</description>
</item>
<item>
<title>Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-first-quarter-220000439</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-first-quarter-220000439</guid>
<pubDate>Fri, 14 Nov 2025 22:00:00 GMT</pubDate>
<description>–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive interim clinical study results from the Phase 1b/2a trial of BB-301, showed a 100% responder rate, with all six patients in Cohort 1 meeting the formal statistical criteria for response to BB-301– –First patient of Cohort 2 successfully treated with BB-301 in Q4</description>
</item>
<item>
<title>Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-inc-announces-pricing-051900767</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-inc-announces-pricing-051900767</guid>
<pubDate>Thu, 06 Nov 2025 05:19:00 GMT</pubDate>
<description>HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 5,930,000 shares of its common stock and a concurrent registered direct offering of 1,481,481 shares of its common sto</description>
</item>
<item>
<title>Benitec Biopharma Inc. Announces Proposed Public Offering</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-inc-announces-proposed-214300305</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-inc-announces-proposed-214300305</guid>
<pubDate>Wed, 05 Nov 2025 21:43:00 GMT</pubDate>
<description>HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced that it has commenced an underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and intends to conduct a conc</description>
</item>
<item>
<title>Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-provides-positive-interim-121000117</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-provides-positive-interim-121000117</guid>
<pubDate>Mon, 03 Nov 2025 12:10:00 GMT</pubDate>
<description>Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted Orphan Drug Designation from both FDA and EMA All six patients enrolled into Cohort 1 met the formal statistical criteria for response to BB-301, representing a 100% response rate Following the administration of BB-301, Cohort 1 patients experienced significant continuing reduction</description>
</item>
<item>
<title>Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-appointment-sharon-120000744</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-appointment-sharon-120000744</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>-Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025-HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platf</description>
</item>
<item>
<title>Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-phase-1b-2a-000000259</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-phase-1b-2a-000000259</guid>
<pubDate>Mon, 03 Nov 2025 00:00:00 GMT</pubDate>
<description>Investor webcast to be held on Monday November 3, 2025 at 8:00 am ESTHAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced that it will provide an update on the six treated patients from Cohort 1 of its Phase 1b/2a Clinical</description>
</item>
<item>
<title>Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-full-2025-200500224</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-full-2025-200500224</guid>
<pubDate>Mon, 22 Sep 2025 20:05:00 GMT</pubDate>
<description>Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interf</description>
</item>
<item>
<title>Benitec Biopharma Provides Operational Updates</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-provides-operational-updates-120000574</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-provides-operational-updates-120000574</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Board Review Has Been Completed for All Six Subjects Enrolled into Cohort 1, and the Data Safety Monitoring Board Recommended Continuation of Subject Enrollment for the Phase 1b/2a Clinical Treatment Study- -Following the Positive Data Safety Monitoring Board Recommendation, Enrollment of Cohort 2 is E</description>
</item>
<item>
<title>Benitec Biopharma Releases Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-third-quarter-110000613</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-third-quarter-110000613</guid>
<pubDate>Wed, 14 May 2025 11:00:00 GMT</pubDate>
<description>HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission.</description>
</item>
<item>
<title>Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-inc-announces-pricing-120000148</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-inc-announces-pricing-120000148</guid>
<pubDate>Tue, 25 Mar 2025 12:00:00 GMT</pubDate>
<description>HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent regis</description>
</item>
<item>
<title>Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-reports-positive-interim-110000123</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-reports-positive-interim-110000123</guid>
<pubDate>Wed, 19 Mar 2025 11:00:00 GMT</pubDate>
<description>-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function Achieved 3-months Post-Treatment with BB-301</description>
</item>
<item>
<title>Benitec Biopharma to Participate in Upcoming Conferences in March</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-participate-upcoming-conferences-120000507</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-participate-upcoming-conferences-120000507</guid>
<pubDate>Wed, 26 Feb 2025 12:00:00 GMT</pubDate>
<description>HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences. TD Cowen 45th Annual Health Care ConferenceDate: March 5, 2025Time of Presentation: 9:50</description>
</item>
<item>
<title>Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-second-quarter-2025-financial-results-and-provides-operational-update</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-releases-second-quarter-2025-financial-results-and-provides-operational-update</guid>
<pubDate>Fri, 14 Feb 2025 05:00:00 GMT</pubDate>
<description>-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking</description>
</item>
<item>
<title>Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference</title>
<link>https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-acceptance-of-late-breaking-oral-abstract-for-the-bb-301-phase-1b2a-clinical-study-at-the-muscular-dystrophy-association-clinical-and-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/benitec-biopharma-ltd-adr/news/benitec-biopharma-announces-acceptance-of-late-breaking-oral-abstract-for-the-bb-301-phase-1b2a-clinical-study-at-the-muscular-dystrophy-association-clinical-and-scientific-conference</guid>
<pubDate>Fri, 14 Feb 2025 05:00:00 GMT</pubDate>
<description>-Interim clinical study updates for the first three Subjects treated with BB-301 in the Phase 1b/2a Clinical Treatment Study to be presented as a</description>
</item>
</channel>
</rss>